Relaxin and the progression of kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 18, Issue 1, 2009, Pages 9-14

  Samuel, Chrishan S ^a,b   Hewitson, Tim D ^b,c  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Angiogenesis; Fibrosis; Relaxin; Renal; Transforming growth factor beta 1; Vasodilation

Indexed keywords

RECOMBINANT RELAXIN; RELAXIN; TRANSFORMING GROWTH FACTOR BETA1;

CONNECTIVE TISSUE; CONTINUOUS INFUSION; HOMEOSTASIS; HUMAN; KIDNEY; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; REVIEW;

ANIMALS; DISEASE PROGRESSION; FIBROSIS; HUMANS; KIDNEY; KIDNEY DISEASES; RELAXIN;

EID: 58149239900     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32831b7096     Document Type: Review

References (34)

1. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005; 12:353-365.
2. Bathgate RAD, Hsueh AJ, Sherwood OD. Physiology and molecular biology of the relaxin peptide family. In: Knobil E, Neill JD, editors. Physiology of reproduction, 3rd ed. New York: Elsevier; 2006. pp. 679-770.
3. Sherwood OD. Relaxin's physiological roles and other diverse actions. Endocr Rev 2004; 25:205-234.
4. Dschietzig T, Bartsch C, Baumann G, et al. Relaxin: a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Ther 2006; 112:38-56.
5. Jeyabalan A, Shroff SG, Novak J, et al. The vascular actions of relaxin. Adv Exp Med Biol 2007; 612:65-87.
6. Nistri S, Bigazzi M, Bani D. Relaxin as a cardiovascular hormone: physiology, pathophysiology and therapeutic promises. Cardiovasc Hematol Agents Med Chem 2007; 5:101-108.
7. Samuel CS, Hewitson TD, Unemori EN, et al. Drugs of the future: the hormone relaxin. Cell Mol Life Sci 2007; 64:1539-1557.
8. Samuel CS, Zhao C, Bond CP, et al. Relaxin-1 -deficient mice develop an age related progression of renal fibrosis. Kidney Int 2004; 65:2054-2064.
9. Bathgate RA, Samuel CS, Burazin TC, et al. Human relaxin gene 3 (H3) and the equivalent mouse relaxin (M3) gene. Novel members of the relaxin peptide family. J Biol Chem 2002; 277:1148-1157.
10. • Hewitson TD, Mookerjee I, Masterson R, et al. Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis. Endocrinology 2007; 148:660-669. This study demonstrates that the absence of endogenous relaxin accelerates the progression of tubulointerstitial disease.
11. Samuel CS, Hewitson TD. Relaxin in cardiovascular and renal disease. Kidney Int 2006;69:1498-1502.
12. Hsu SY, Nakabayashi K, Nishi S, et al. Activation of orphan receptors by the hormone relaxin. Science 2002; 295:671-674.
13. Masterson R, Hewitson TD, Kelynack K, et al. Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro. Nephrol Dial Transplant 2004; 19:544-552.
14. Hocher B, Ziebig R, Krause R, et al. Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease. Circulation 2004; 109:2266-2268.
15. Lekgabe ED, Royce SG, Hewitson TD, et al. The effects of relaxin and estrogen deficiency on collagen deposition and hypertrophy of nonreproductive organs. Endocrinology 2006; 147:5575-5583.
16. Baylis C. Age-dependent glomerular damage in the rat. Dissociation between glomerular injury and both glomerular hypertension and hypertrophy. Male gender as a primary risk factor. J Clin Invest 1994; 94:1823-1829.
17. Muller V, Szabo A, Viklicky O, et al. Sex hormones and gender-related differences: their influence on chronic renal allograft rejection. Kidney Int 1999; 55:2011-2020.
18. Garber SL, Mirochnik Y, Brecklin CS, et al. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int 2001; 59:876-882.
19. Garber SL, Mirochnik Y, Brecklin C, et al. Effect of relaxin in two models of renal mass reduction. Am J Nephrol 2003; 23:8-12.
20. McDonald GA, Sarkar P, Rennke H, et al. Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal fibrosis in vivo. Am J Physiol Renal Physiol 2003; 285:F59-67.
21. Lekgabe ED, Kiriazis H, Zhao C, et al. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 2005; 46:412-418.
22. Danielson LA, Welford A, Harris A. Relaxin improves renal function and histology in aging Munich Wistar rats. J Am Soc Nephrol 2006; 17:1325-1333.
23. Heeg MH, Koziolek MJ, Vasko R, et al. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int 2005; 68:96-109.
24. Samuel CS, Unemori EN, Mookerjee I, et al. Relaxin modulates cardiac fibroblast proliferation, differentiation and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 2004; 145:4125-4133.
25. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, et al. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 2007; 74:196-206.
26. Schnaper HW, Hayashida T, Hubchak SC, et al. TGF-beta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol 2003; 284:F243-252.
27. Jeyabalan A, Conrad KP. Renal function during normal pregnancy and preeclampsia. Front Biosci 2007; 12:2425-2437.
28. Dschietzig T, Bartsch C, Richter C, et al. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1 -mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circ Res 2003; 92:32-40.
29. •• Jeyabalan A, Novak J, Doty KD, et al. Vascular matrix metalloproteinase-9 mediates the inhibition of myogenic reactivity in small arteries isolated from rats after short-term administration of relaxin. Endocrinology 2007; 148:189-197. This study demonstrates the significance of the relaxin-mediated promotion of gelatinase activity to its vasodilatory effects in the kidney.
30. Unemori EN, Erikson ME, Rocco SE, et al. Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women. Hum Reprod 1999; 14:800-806.
31. Unemori EN, Lewis M, Constant J, et al. Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regen 2000; 8:361-370.
32. • Formigli L, Perna AM, Meacci E, et al. Paracrine effects of transplanted myoblasts and relaxin on postinfarction heart remodelling J. Cell Mol Med 2007; 11:1087-1100. This study is the first to demonstrate the complementary effects of relaxin to stem cell-based therapies in the setting of ischemic heart disease.
33. Kang DH, Hughes J, Mazzali M, et al. Impaired angiogenesis in the remnant kidney model. II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001; 12:1448-1457.
34. Smith MC, Danielson LA, Conrad KP, et al. Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers. J Am Soc Nephrol 2006; 17:3192-3197.